Nurix Therapeutics, Inc.
NRIX
$9.55
$0.020.21%
NASDAQ
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.43% | -35.73% | -39.55% | -32.38% | -83.49% |
| Total Depreciation and Amortization | 24.59% | 6.17% | 27.41% | 22.52% | 22.74% |
| Total Amortization of Deferred Charges | -- | -- | -7.14% | -- | -- |
| Total Other Non-Cash Items | 14.93% | -12.34% | -16.84% | -26.41% | -13.98% |
| Change in Net Operating Assets | -447.14% | -37.36% | -99.24% | 81.73% | -12.04% |
| Cash from Operations | -59.08% | -45.62% | -282.66% | -2.54% | -114.98% |
| Capital Expenditure | -38.10% | -20.84% | 18.57% | 4.55% | -79.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 157.44% | -24.43% | -1,076.72% | -175.26% | -387.53% |
| Cash from Investing | 154.55% | -28.10% | -879.73% | -193.69% | -399.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -9.30% | 2,864,485.71% | 2,586.03% | 950,968.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -9.30% | 2,864,485.71% | 2,586.03% | 950,908.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -87.54% | -607.96% | -11.12% | -6.56% | 163.82% |